Despite its importance, HTA faces several challenges in cancer care:
Rapid Technological Advancements: The pace of innovation in cancer treatment can outstrip the ability of HTA processes to keep up, leading to delays in assessment and adoption. Limited Data: New treatments often enter the market with limited long-term data, making it challenging to assess their true effectiveness and cost-effectiveness. Patient Heterogeneity: Cancer is a heterogeneous disease, and treatments may have varying effects across different patient populations, complicating the assessment process. Stakeholder Engagement: Balancing the interests and perspectives of various stakeholders, including patients, healthcare providers, and industry, is a complex task.
